Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events

NCT07712380 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07712380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
May 4, 2029
Enrollment
450 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease